Table 1. Conditional Brca1 mouse models.
| Brca1 mutation | p53 co-mutation | Cre transgene | Genetic background | Mean tumor latency (months) | Triple-negative tumours | Basal -like tumours | Initial platinum sensitivity | Platinum resistance | Initial PARPi sensitivity | PARPi resistance | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MMTVcre;Brca1F11/Δ11 WAPcre;Brca1F11/Δ11 (Xu et al, 1999a) | Brca1 Δ11 | No | MMTVcre or WAPcre | NIH-BL(S) | >13 | — | Noa | — | — | — | — |
| MMTVcre; Brca1F11/F11;p53+/− WAPcre; Brca1F11/F11;p53+/− (Brodie et al, 2001) | Brca1 Δ11 | p53 Null | MMTVcre or WAPcre | NIH-BL(S), C57BL/6, 129/Sv | 8 | Nob | Noa | — | — | — | — |
| WAPcrec;Brca1F11/F11; p53F5–6/F5–6 (Poole et al, 2006) | Brca1 Δ11 | p53 Δ5–6 | WAPcre c | C57BL/6, 129/Sv or C57BL/6, BALB/c | 7 | Noc | Noa | Yes | Yes | — | — |
| BLGcre; Brca1F22–24/F22–24; p53+/− (McCarthy et al, 2007) | Brca1 Δ22–24 | p53 Null | BLGcre | C57BL/6, 129/Sv | 7 | Yes | Yes | — | — | — | — |
| K14cre; Brca1F5–13/F5–13; p53F2–10/F2–10 (Liu et al, 2007) | Brca1 Δ5–13 | p53 Δ2–10 | K14cre | FVB, 129/Ola | 7 | Yes | Yes | Yes | No | Yes | Yes |
| WAPcre;Brca1F1/F1 (Shakya et al, 2008) | Brca1 Δ1 | No | WAPcre | C57BL/6, 129/Sv | 17 | Yes | Yes | — | — | — | Yes |
Abbreviations: —= not determined.
a
Heterogeneous mammary tumour spectrum.
b
ERBB2-positive and ER-negative, PR status not determined.
c
PR-positive, ER and ERBB2 status not determined.